Lake Street analyst Frank Takkinen raised the firm’s price target on Envoy Medical to $6 from $3 and keeps a Buy rating on the shares. 2023 was an important year for Envoy with a public market debut and completion of follow-up in the early feasibility study for Acclaim and in 2024, Envoy could achieve two key value-generating catalysts when kicking off a pivotal trial for Acclaim and repositioning Esteem for future Medicare reimbursement, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COCH:
- Envoy Medical to Participate in the LD Micro Invitational XIV Conference April 8 – 9, 2024
- Envoy Medical reports FY23 EPS ($2.38) vs ($1.57) last year
- Envoy Medicalto participates in a conference call hosted by Northland
- Envoy Medical to Participate in the 36th Annual ROTH Conference
- COCH Stock trading resumes